Comparative Pharmacology
Head-to-head clinical analysis: NUPLAZID versus TOVALT ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUPLAZID versus TOVALT ODT.
NUPLAZID vs TOVALT ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT2A receptor inverse agonist and antagonist; also has moderate affinity for 5-HT2C and 5-HT1A receptors.
Tovalt ODT (selegiline) is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). At therapeutic doses, it inhibits MAO-B more selectively than MAO-A, leading to increased levels of dopamine in the brain.
34 mg orally once daily.
20 mg sublingually as needed for BTP, with a minimum interval of 2 hours between doses; maximum 4 doses per day.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours (range 40-70 hours), allowing once-daily dosing.
Terminal elimination half-life approximately 40–60 hours after multiple dosing; clinical context: reaches steady-state after 2–3 weeks.
Fecal (approximately 60%) as unchanged drug and metabolites; renal (approximately 13%) as unchanged drug and metabolites.
Primarily hepatic metabolism; 70–80% as inactive metabolites in urine, <5% unchanged in urine, 20–30% fecal.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic